Last reviewed · How we verify
NCT05538221
Reliability of a Gait Analysis System
trial testing SILEMA in Gait Analysis in 18 participants. Completed in 4 November 2022.
4 November 2022
Quick facts
| Lead sponsor | Centro Integral de Neurologia y Especialidades Afines, Argentina |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 18 |
| Start date | 20 October 2022 |
| Primary completion | 4 November 2022 |
| Estimated completion | 4 November 2022 |
| Sites | 1 location across Argentina |
Drugs / interventions tested
- SILEMA
Conditions studied
- Gait Analysis — all drugs for Gait Analysis →
Sponsor
Centro Integral de Neurologia y Especialidades Afines, Argentina
Who can join
Adults 18 to 65, any sex, with Gait Analysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gait disturbances can be observed in all age groups, and may be due to different conditions, such as advanced age, stroke, head trauma, spinal cord injury, cerebral palsy, myelomeningocele, among others. The aforementioned gait disorders are associated with an increased risk of falls (which can cause major fractures or head trauma), decreased mobility, loss of independence, cardiovascular pathology, and decreased quality of life. In order to improve a given abnormal gait pattern, an objective assessment of gait is necessary. There are several methods to carry out gait evaluations, like Instrumented Gait Analysis (High cost, time-consuming, qualified professionals needed) and the ones based on observation (limited reliability and validity). An alternative, is the use of video-based systems. SILEMA (Computer System for Gait Study Laboratories in Argentina) is a video-based low-cost gait analysis system that measures temporo-spatial (speed, step length, cadence, stance and swing times) and joint kinematic (Hip, Knee, Ankle) parameters. Its reliability has not been reported yet; thus the primary aim of this study is to determine both the "intra-evaluator" (same evaluator, different sessions) and "inter-evaluator" (same session, different evaluators) reliability.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05538221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gait Analysis
Currently open trials in the same condition.
- NCT06994793 — Validity and Reliability of Gait and Jump Parameters Measured by the iSen Device in Healthy Adults · recruiting
- NCT06304077 — Restorative Environments for Gait Therapy with VR · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05538221 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centro Integral de Neurologia y Especialidades Afines, Argentina
- Last refreshed: 8 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05538221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing